Sg3 Management, LLC Cassava Sciences Inc Call Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $478,584 - $743,376	-20,400 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $620,386 - $984,767	22,300 Added 109.31%	42,700 $1.26 Million
Q3 2022 May 15, 2023	SELL	$16.33 - $51.06 $364,158 - $1.14 Million	-22,300 Reduced 52.22%	20,400 $853,000
Q3 2022 Nov 14, 2022	SELL	$16.33 - $51.06 $75,117 - $234,876	-4,600 Reduced 18.4%	20,400 $853,000
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $430,500 - $961,750	-25,000 Reduced 50.0%	25,000 $703,000
Q4 2021 Feb 15, 2022	SELL	$36.77 - $90.91 $1.65 Million - $4.09 Million	-45,000 Reduced 47.37%	50,000 $2.19 Million
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $3.55 Million - $11.5 Million	85,000 Added 850.0%	95,000 $5.9 Million
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $2.57 Million - $7.18 Million	-80,000 Reduced 88.89%	10,000 $854,000
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $638,100 - $7.92 Million	90,000 New	90,000 $4.05 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.06B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.